Skip to content
Screener

Ionis Pharmaceuticals IONS Common Stock Shares Issued

Common Stock Shares Issued at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
255.3M+21.6%
ALN
Alnylam PharmaceuticalsALNY
133.7M+2.1%
CalAmp logo
CalAmpCAMP
51.9M+158%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
205.9M
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
19.9M+2.6%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.46B+45.4%
Enterprise value$9.37B+33.8%
P/S10.8×+3.9×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemJune 30, 2026December 31, 2025
Long-term obligations28,43528,118
Total liabilities2,554,7643,034,747
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively166163
Additional paid-in capital3,311,8373,145,402
Accumulated other comprehensive loss(33,897)(25,281)
Accumulated deficit(2,838,369)(2,631,195)
Total stockholders' equity439,737489,089

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's common stock shares issued?
Ionis Pharmaceuticals (IONS) reported common stock shares issued of 165.6M in Q2 2026.
How has Ionis Pharmaceuticals's common stock shares issued changed year-over-year?
Ionis Pharmaceuticals's common stock shares issued increased by 4.0% year-over-year, from 159.2M to 165.6M.
What is the long-term trend for Ionis Pharmaceuticals's common stock shares issued?
Over 5 years (2020 to 2025), Ionis Pharmaceuticals's common stock shares issued has grown at a 3.1% compound annual growth rate (CAGR), from 140.4M to 163.3M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Ionis Pharmaceuticals's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude